APA (7th ed.) Citation

Knight, T. E., Broglie, L., Sharma, A., Qayed, M., & Yanik, G. A. (2025). Why are Higher CD34+ Cell Doses Associated with Improved Outcomes among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors – But Not for High-Risk Neuroblastoma? Pediatric Hematology & Oncology, 42(1), 63. https://doi.org/10.1080/08880018.2024.2420924

Chicago Style (17th ed.) Citation

Knight, Tristan E., Larisa Broglie, Akshay Sharma, Muna Qayed, and Gregory A. Yanik. "Why Are Higher CD34+ Cell Doses Associated with Improved Outcomes Among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors – But Not for High-Risk Neuroblastoma?" Pediatric Hematology & Oncology 42, no. 1 (2025): 63. https://doi.org/10.1080/08880018.2024.2420924.

MLA (9th ed.) Citation

Knight, Tristan E., et al. "Why Are Higher CD34+ Cell Doses Associated with Improved Outcomes Among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors – But Not for High-Risk Neuroblastoma?" Pediatric Hematology & Oncology, vol. 42, no. 1, 2025, p. 63, https://doi.org/10.1080/08880018.2024.2420924.